ArticleJournal of neurology2008
Lewy body dementia and Parkinson's disease with dementia.
Article in Journal of neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- FoxO1 Alleviates the Mitochondrial ROS Levels Induced by α-Synuclein Preformed Fibrils in BV-2 Microglial Cells.Inflammation · 2025Article
- DJ-1 protects cell death from a mitochondrial oxidative stress due to GBA1 deficiency.Genes & genomics · 2024Article
- Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia.Health science reports · 2024Review
- Exploring Influence of Production Area and Harvest Time on Specialized Metabolite Content ofAntioxidants (Basel, Switzerland) · 2024Article
- Parkinson's disease: Are gut microbes involved?Brain and behavior · 2023Review
- α-Synuclein Preformed Fibrils Bind to β-Neurexins and Impair β-Neurexin-Mediated Presynaptic Organization.Cells · 2023Article
- Epigenetic modification in Parkinson's disease.Frontiers in cell and developmental biology · 2023Review
- Anti-Aging and Neuroprotective Properties ofNutrients · 2022Article
- α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice.Nature communications · 2022Article
- Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson's disease.Cell death & disease · 2022Article
- Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies.Frontiers in synaptic neuroscience · 2020Review
- Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.Neuron · 2019Article
- The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ε4 Allele Variant in Patients With Dementia.International journal of tryptophan research : IJTR · 2019Article
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Article
- Parkinson Disease and Melanoma: Confirming and Reexamining an Association.Mayo Clinic proceedings · 2017Article
- Synucleinopathies: common features and hippocampal manifestations.Cellular and molecular life sciences : CMLS · 2017Review
- Neurophysiological biomarkers for Lewy body dementias.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2016Review
- A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease.Journal of Alzheimer's disease & Parkinsonism · 2013Article
- Phospholipase C beta 4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is characterized by its motor impairment. However, non-motor symptoms such as psychiatric disorders, autonomic disturbances and sleep disorders frequently complicate the course of the disease. In particular, psychiatric disturbances including cognitive impairment, depression and psychosis impact these patients considerably. Approximately 31 % of PD patients suffer from cognitive impairment and dementia. Currently, two different clinical presentations are distinguished in PD patients, who present with dementia: Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB), which are two different presentations of a single underlying disease process leading to the deposition of alpha-synuclein. Clinically, PDD is distinguished from DLB alone by the different temporal manifestations of extrapyramidal motor symptoms. Dementia is characterized by a subtle onset and progressive cognitive decline with a predominant dysexecutive syndrome, which can be accompanied by different behavioral symptoms such as hallucinations, depression, anxiety and sleep disorders. Dysregulation of different neurotransmitters has been associated with cognitive decline, but reduced cholinergic transmission is currently thought to be the pivotal mechanism in the development of cognitive dysfunction. Therefore, cholinesterase inhibitors are used in the treatment of dementia and accompanying behavioral symptoms in PDD and DLB. The occurrence of dementia impacts not only the patients themselves but also their care-givers and family.This article focuses on the clinical issues related to both disorders and is based on a meeting of experts which took place in April 2008 in Dresden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.